GET DAILY SIGNALSCabaletta Bio (CABA): What the $15 Analyst Target and 930% Upside Really Signal
Key Takeaways
- The central target of $15 is the arithmetic mean of the verified analyst price targets reviewed for Cabaletta Bio, a clinical-stage CAR T cell therapy developer.
- At a recent price near $1.46, reaching $15 would require a gain of roughly 930% — an extremely large move reflecting deep clinical-stage uncertainty rather than a modest re-rating.
- Individual analyst targets span a very wide range, from $3 (Wells Fargo) to $30, underscoring sharp disagreement about the odds of clinical and regulatory success.
- The strongest supports are positive early data for lead candidate rese-cel, a $225 million cash runway into mid-2027, and a 10-year manufacturing agreement with Cellares.
- The biggest risks are binary clinical-trial outcomes, ongoing cash burn, heavy dilution, and a stock that has fallen about 65% from its 52-week high.
- For more on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for additional detail.
Analyst Price Targets and the Range of Views
Cabaletta Bio, Inc. (NASDAQ: CABA) draws attention from a small group of sell-side analysts whose opinions differ sharply, which is typical for a binary biotechnology story. The $15 central target here is simply the arithmetic mean of verified individual targets rather than an official consensus figure. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Targets stretch from about $3 at Wells Fargo, which lowered its figure from $4 in August 2026, up to $30 at the high end. Other notes include H.C. Wainwright at $16, Cantor Fitzgerald at $15, Jefferies at $14, Citigroup at $13, Mizuho at $10, and Guggenheim at $25. The broad $3-to-$30 spread shows how little agreement exists on the probability of rese-cel reaching approval and commercialization.
Current Valuation and the Scale of the Move
Cabaletta Bio trades near $1.46, giving it a market capitalization around $247 million and a 52-week range of roughly $1.32 to $4.23. Hitting the $15 central target would mean an increase of approximately 930%, a sizable jump driven by clinical milestones rather than traditional earnings metrics.
With no product revenue, the share price hinges on clinical data and cash reserves. The company held about $225 million in cash and investments as of mid-2026, expected to support operations into mid-2027, following a $150 million equity offering in May 2026 that included participation from Eli Lilly.
Key Supports for Potential Progress
The case centers on rese-cel, a CD19-directed CAR T cell therapy aimed at autoimmune conditions such as myositis and lupus. Early results have shown durable, drug-free responses, with registrational RESET-Myositis data guided for mid-2027 and a BLA submission targeted for the second half of 2027. A 10-year manufacturing deal with Cellares helps address scale, while work on preconditioning-free dosing could strengthen the commercial profile. Positive pivotal readouts or partnership funding would serve as natural catalysts.
Primary Risks to Consider
Clinical outcomes remain the dominant uncertainty, as most indications are still in Phase 1/2 and pivotal data are not expected until 2027. Any safety concerns or weaker efficacy could lower approval odds. Persistent net losses, cash burn, and likely future dilution also factor into the share count. Competition from larger players in autoimmune CAR T, regulatory challenges, and the broader reality that many early-stage biotechs do not reach commercialization add to the risk profile. The stock’s decline of about 65% from its 52-week high reflects ongoing investor caution.
Technical Picture and Levels to Watch
The shares sit in a clear downtrend. The recent low near $1.32 offers nearby support, while the $4.23 area marks a significant resistance point from the prior high. On any recovery, round numbers such as $5 and $10 could act as psychological milestones, though the current technical structure does not yet confirm a firm base.
Time Horizon and Items to Monitor
Analyst targets generally embed a 12-month horizon but incorporate longer-term assumptions for clinical-stage names. Key items to follow include the next quarterly update around mid-November 2026, any cash runway updates, higher-dose preconditioning-free data expected late 2026, initial RESET-SLE results, and progress toward the mid-2027 RESET-Myositis readout and BLA filing. From what I see, these milestones will matter far more than the average target itself.
Exploring Systematic Signals
For traders looking at volatile names like this, Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to track thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical behavior, and data-driven analysis. I’m watching this closely as a way to spot potential shifts more systematically than manual review alone.
Using AI Tools for Deeper Insights
In my own process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check technical and market-driven signals on clinical-stage names like this one. The platform continuously scans conditions across a wide universe and can surface trend changes that complement traditional fundamental work. It has become a practical part of how I monitor positions and identify when sentiment may be shifting.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CABA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 13, 2026
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 33 cases where CABA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CABA just turned positive on October 22, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +14.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 221 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.171) is normal, around the industry mean (3.037). P/E Ratio (-1.054) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases
Industry Biotechnology
Advertisement